Unknown

Dataset Information

0

Applicability of the pittsburgh staging system for advanced cutaneous malignancy of the temporal bone.


ABSTRACT: The objectives are to evaluate the applicability of the Pittsburgh staging system (PSS) (designed for primary temporal bone malignancies) to advanced periauricular cutaneous malignancies with temporal bone involvement and to study treatment outcomes and prognostic factors predicting recurrence-free survival. Ten patients with advanced periauricular cutaneous malignancy with temporal bone involvement were identified. Patients with primary temporal bone or parotid gland malignancies were excluded. All patients were clinically T4 at presentation by the American Joint Committee on Cancer (AJCC) staging system. Using Pittsburgh staging, six were T1 (stage I) and four were T4 (stage III). The mean follow-up was 13.6 months (3 to 24 months). Patients with basal cell carcinoma were managed with wide local excision and lateral temporal bone resection (WLE/LTBR) without adjuvant therapy. Two of three (66%) are alive and free of disease; one patient died of other causes. Treatment for squamous cell carcinoma patients involved multimodality therapy. Kaplan-Meier survival curves show a worse prognosis in terms of disease-specific survival for patients with higher-staged PSS tumors. This did not reach statistical significance. The PSS may provide additional prognostic information on advanced cutaneous malignancies of the temporal bone over the more widely used AJCC staging system. However, further prospective multicenter studies with larger sample size are required to validate our findings. Basal cell carcinoma was well controlled with WLE/LTBR alone without adjuvant therapy, whereas squamous cell carcinoma required multimodality therapy: WLE/LTBR and postoperative radiation with or without chemotherapy.

SUBMITTER: Gaudet JE 

PROVIDER: S-EPMC3134817 | BioStudies | 2010-01-01

SECONDARY ACCESSION(S): 10.1055/s-0030-1253575

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6756576 | BioStudies
1000-01-01 | S-EPMC5817486 | BioStudies
2017-01-01 | S-EPMC5615338 | BioStudies
2011-01-01 | S-EPMC3312127 | BioStudies
2017-01-01 | S-EPMC5548559 | BioStudies
2007-01-01 | S-EPMC1800369 | BioStudies
2016-01-01 | S-EPMC5341821 | BioStudies
2020-01-01 | S-EPMC7352543 | BioStudies
2017-01-01 | S-EPMC5548580 | BioStudies
2015-11-20 | E-GEOD-66638 | ArrayExpress